 Accession No.: BL-12-D10126

Department of Pathology
Center for Advanced Molecular Diagnostics Unit Number(s): BWH 243-05-823
75 Francis Street, Boston, MA 02115 DFCI 455-27-4
Tel (857) 307-1500 Fax (857) 307-1522 Patient Name: THEBERGE, RICHARD J
Birth Date: 8/1/1956
Age Sex: 55 Year old Male 



 

Specimen Submitted Facility Lab Control Number/MRN Hospital Location

A. Molec Dx Fixed tissue/block DFCI Doctor Office
Received Report Date Procedure Date
4/4/2012 4/14/2012

Physician (s)/Copies to:
JOSEPH P FÂ®ER, MO

Test Performed - MDOMAP4_B

Test Description - \OncoMap 4

Accession numbers on blocks submitted - BS-09-D50765

Original Pathologic Diagnosis - Colon Adenocarcinoma

Original Specimen Collection Date -

Estimated percentage of neoplastic cells in submitted specimen - 60%

CLINICAL DATA:

Clinical Diagnosis:
RESULTS
DNA VARIANTS:

PIK3CA c.1633G>A (p.Glu545Lys, p.E545K,| GAG>AAG), exon 9

INTERPRETATION:

**To date, there is little published evidence relating these genetic changes to cancer
biology or treatment response precluding the use of this information for decisions
regarding patient management outside the context of clinical research.

NEGATIVE for following mutations with clinical relevance for this tumor type: AKT1
p.E17K, BRAF p.V600A, BRAF p.V600D, BRAF p.V600E, BRAF p.V600E, BRAF p.V600K, BRAF
p.V600L, BRAF p.V600L, BRAF p.V600M, BRAF p.V600R, EGFR p.D770_N77linsN, EGFR
p.E746_A750>V, EGFR p.E746_1 A750del, EGFR p.E746_A750del, EGFR p.E746_S752>A, EGFR
p.E746_S752>V, EGFR p.E746_' ; T751>A, EGFR p. E746 _' T751del, EGFR p.E746K, EGFR p.G719A, EGFR
p.G719C, EGFR p.G719D, EGFR p.G719S, EGFR p. I744_] A750>VK, EGFR p.L747_A750>P, EGFR

JOSEPH P EDER, M.D. CLIA: 22D2040971
Dana-Farber Cancer Institute Laboratory Director:
HEMATOLOGY & ONCOLOGY Dr. Neal Lindeman
44 Binney St.

Boston, MA 02115
 




 

.L747_A750>P, EGFR p.L747_E749del, EGFR p.L747_P753>Q, EGFR p.L747_P753>S, EGFR
.L747_R748>FP, EGFR p.L747_8752del, EGFR p.L747_1751>P, EGFR p.L747_1751>S, EGFR
.L747_T751del, EGFR p.L858R, EGFR p.L858R, EGFR p.L858R, EGFR p.L861Q, EGFR
.N771_P772>SVDNR, EGFR p.S752_1759del, EGFR p.S768I, EGFR p.1T790M, EGFR
.V769_D770insASV, EGFR p.V769_D770insASV, KRAS p. A146, KRAS p.A59T, KRAS p.G12A, KRAS
.G12C, KRAS p.G12D, KRAS p.G12R, KRAS p.G12S, KRAS p.G12V, KRAS p.G13A, KRAS p.G13C,
KRAS p.G13D, KRAS p.G13R, KRAS p.G13S, KRAS p.G13V, KRAS p.L19F, KRAS p.L19F, KRAS
p.Q22K, KRAS p.Q61E, KRAS p.Q61H, KRAS p.Q61H, KRAS p.Q61K, KRAS p.Q61L, KRAS p.Q61P,
KRAS p.Q61R

TD 'D'S D'S

The following assays did not yield) satisfactory results:

ABL1_F317L, ABL1_Y253F, CDKN2A_W110*, CSF1R_Y969C, CSF1R_Y969F, EGFR_G735S,
EGER _ P772 -H773insvV, FGFR1_ $125L, JAK3_! P1327, KIT_K550 )_K558del, KIT | K558_E562del,
PDGFRA | S566 1 E571>K, PIK3R1 _K459 | SA60>N, RET] E768D, TP53 , R273C, VHL , 1158Q

TEST INFORMATION

Background:

Somatic mutations in oncogenes and tumor-suppressor genes contribute to the
pathogenesis and evolution of human cancers. These alterations can provide prognostic and
predictive information and stratify cancers for targeted therapeutic information.

Method:

We have developed a multiplexed assay to detect somatic mutations in tumor DNA
extracted from fresh, frozen or formalin-fixed paraffin-embedded samples. The assay
OncoMap 4 detects mutations in 472 different loci from 41 cancer genes. DNA is isolated
from tissue containing at least 50% tumor nuclei and analyzed by multiplex PCR
amplification of the region containing the nucleotide variant of interest, an optimized
primer extension reaction to generate allele-specific DNA products, and chip-based mass
spectrometry for separation and analysis of the DNA analytes (Sequenom MassARRAY 4). The
41 genes are: ABL1, AKT1, AKT2, APC, BRAF, CDK4, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2,
FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ,)| GNAS, HRAS, IDH1, IDH2, JAK2,-JAK3, KIT, KRAS,
MAP2K1, MET, MLH1, MYC, NPM1, NRAS, PDGFRA, PIK3CA, PIK3R1, PTEN, RB1, RET,.SRC, STK11,
TP53, VHL. A full. listing of the loci tested can be found at PCMP or by contacting the
Center for Advanced Molecular Diagnostics (857-307-1500).

These tests were developed and their performance characteristics determined by the
, . They have not been
cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that
such clearance or approval is not necessary.

REFERENCES :

By his/her signature below, the senior physician certifies that he/she personally
reviewed all the laboratory data of the described specimen(s) and rendered or confirmed
the diagnosis(es) related thereto.
